May 19/04

A pair of studies at UCLA's Jonsson Cancer Center taking laboratory science to the patient bedside found that combining the molecularly targeted therapy Herceptin with a specific chemotherapy combination resulted in significant tumor response rates and longer relapse-free periods in women with an aggressive form of advanced breast cancer...

Read the rest of the article at:
http://www.medicalnewstoday.com/index.php?newsid=8460